Mersana Therapeutics reports positive phase 1 data for novel ADC in triple-negative breast cancer

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical innovator, has announced promising early clinical data from its Phase 1 trial evaluating emiltatug ledadotin (Emi-Le; XMT-1660), an antibody-drug ... Read More